Biotech Co. Investors' FDA Convo Suit Survives Dismissal Bid
A Manhattan federal judge on Tuesday pared down a proposed class action alleging biotech company Acer Therapeutics and two of its executives misrepresented its conversations with the U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article